U.S. Sen. Cindy Hyde-Smith (R-Miss.) said Thursday she wants a full review of the data that led to the Food and Drug Administration’s recent decision to end requirements for in-person delivery of abortion pills. chemicals, a decision that puts women’s health at risk.
Hyde-Smith challenged the ‘mail-order abortion’ ruling while questioning FDA Commissioner Robert Califf, MD, who testified Thursday at a Senate Farm Appropriations Subcommittee hearing to consider the request. of the agency’s FY2023 budget. In February, Hyde-Smith sent a letter to Califf seeking to reverse the December decision to remove in-person distribution requirements from the Risk Assessment and Mitigation Strategy (REMS) for mifepristone.
“Your response, which I received last week, indicated that you had performed a ‘comprehensive review’ of the REMS program and concluded that even without the in-person dispensing requirement, the drug would be ‘safe and effective’. “I and many others disagree with this. There is plenty of evidence to show that these chemical abortion pills are dangerous for women who take them and can be extremely dangerous in certain situations,” Hyde-Smith said. .
“It’s the FDA’s job and your job as commissioner to protect patients by ensuring drug safety. The stronger REMS that had been in place since 2019 included safeguards to protect patients from unnecessary risks posed by the drug,” she added.
Hyde-Smith, citing Cardiff’s “unequivocal belief that your review was comprehensive,” said she will request information on any literature used by the FDA to expand access to the abortion-inducing drug.
Hyde-Smith, who highlighted Charlotte Lozier Institute research on the dangers of mail-order abortions in a March op-ed, expressed concern that chemical abortions now account for the majority of all abortions in the states. United States, including an 11% jump in Mississippi in 2019.
“This is, of course, a serious concern to me after talking to my OB/GYN friends. As you said you want to see the number of abortions go down, what are you doing to reverse this increasing trend chemical abortions and actually help bring the numbers down?” Hyde-Smith asked Califf.
In relation to this issue, Hyde-Smith and US Congressman Bob Latta (R-Ohio) introduced in January 2021 the Support and Value Expectant (SAVE) Moms and Babies Act (S.78 and HR.554 ) to prevent labeling changes for already-approved abortifacient products; prevent providers from dispensing these drugs remotely, by mail or via telemedicine; and prevent FDA approval of new chemical abortifacient drugs.